We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Baseline fat fraction is a strong predictor of disease progression in Becker muscular dystrophy.
- Authors
Veeger, Thom T. J.; van de Velde, Nienke M.; Keene, Kevin R.; Niks, Erik H.; Hooijmans, Melissa T.; Webb, Andrew G.; de Groot, Jurriaan H.; Kan, Hermien E.
- Abstract
In Becker muscular dystrophy (BMD), muscle weakness progresses relatively slowly, with a highly variable rate among patients. This complicates clinical trials, as clinically relevant changes are difficult to capture within the typical duration of a trial. Therefore, predictors for disease progression are needed. We assessed if temporal increase of fat fraction (FF) in BMD follows a sigmoidal trajectory and whether fat fraction at baseline (FFbase) could therefore predict FF increase after 2 years (ΔFF). Thereafter, for two different MR‐based parameters, we tested the additional predictive value to FFbase. We used 3‐T Dixon data from the upper and lower leg, and multiecho spin‐echo MRI and 7‐T 31P MRS datasets from the lower leg, acquired in 24 BMD patients (age: 41.4 [SD 12.8] years). We assessed the pattern of increase in FF using mixed‐effects modelling. Subsequently, we tested if indicators of muscle damage like standard deviation in water T2 (stdT2) and the phosphodiester (PDE) over ATP ratio at baseline had additional value to FFbase for predicting ∆FF. The association between FFbase and ΔFF was described by the derivative of a sigmoid function and resulted in a peak ΔFF around 0.45 FFbase (fourth‐order polynomial term: t = 3.7, p <.001). StdT2 and PDE/ATP were not significantly associated with ∆FF if FFbase was included in the model. The relationship between FFbase and ∆FF suggests a sigmoidal trajectory of the increase in FF over time in BMD, similar to that described for Duchenne muscular dystrophy. Our results can be used to identify muscles (or patients) that are in the fast progressing stage of the disease, thereby facilitating the conduct of clinical trials.
- Subjects
BECKER muscular dystrophy; MYOTONIA congenita; DISEASE progression; DUCHENNE muscular dystrophy; MUSCLE weakness
- Publication
NMR in Biomedicine, 2022, Vol 35, Issue 7, p1
- ISSN
0952-3480
- Publication type
Article
- DOI
10.1002/nbm.4691